Starting a GLP-1 medication with endometriosis The standard approach applies: start low, titrate slowly
En general, el 37,4% de los pacientes que recibieron semaglutida para la obesidad lograron una reduccin del peso corporal del 10% o ms, en comparacin con el 16,6% de los pacientes que recibieron semaglutida para la diabetes tipo 2
If countries get the combination right, "the impact on bringing down levels of the people who are obese, and the impact particularly on diabetes
This ensures that the medications prescribed align with your health profile and weight loss objectives
Importantly, the nuance in offering GLP-1s is that employers want to ensure they get into the hands of the employees that stand to benefit most and thus get the most value out of the medicines, so I expect we will see additional restrictions put in place to control coverage of these medicines, in the form of prior authorizations and other controlled access